Results : let's start with the results of a successful collaboration story
In the early days of the Coronavirus Pandemic, Vir Biotechnology, a biotech company located in San Francisco, California, quickly mobilized its resources to tackle the virus. The objective was clear: to find a drug that could not only prevent infection, but also treat COVID-19. With a clear mission and a dedicated team, Vir succeeded in an unprecedented manner. In just 7 months, the company discovered, developed, and began clinical trials for Sotrovimab, a monoclonal antibody that later on proved to treat COVID-19. Typically, this process can take up to 3-4 years.
This achievement, made possible through the exceptional science and hard work of the team at Vir Biotechnology, was also aided by the coordination, organization, and support provided by our solutions. As a long-standing partner of Vir, we are honored to have played a role in supporting the company with their complex internal processes and contributing to this historic achievement.
Fighting Coronavirus with human Antibodies
Experience how Vir Biotechnology made the transition from antibody discovery to first patient dosed in just 7 months - a true testament of great science enabled by the power of smooth processes and great information management.
How : let's see how our solution developed
With our help, Humabs embarked on a digitalization journey that began with the implementation of a custom-built software solution designed to streamline and standardize key processes and data management. This was a gradual process that started with the most critical processes, such as laboratory experiments, project and task management and sample management.
As Humabs adapted to the new processes, we continued to add more functionality to the software solution, including features for managing instrument inventory and booking, commercial purchase orders, outgoing and incoming shipments, collaborators and CROs, and protein sequences.
Through this process, Humabs was able to grow organically in a fast and efficient manner, thanks to the standardization of processes and the high degree of organization and data availability provided by our software solution. This allowed the company to react quickly to new challenges and to create high-quality data, enabling Humabs to continue to innovate and evolve, both scientifically and organisationally. Today, Humabs Biomed and Vir Biotechnology rely on our software solution as a fundamental tool for managing information and processes within the company, and our partnership with Humabs is ongoing, as our solution and consulting will easily adapt to the company's future growth and evolution.
Start : let's see the starting point of the collaboration
Our partnership with Vir Biotechnology began in 2013, when we first began working with Humabs Biomed, a biotech company that would later be acquired by Vir in 2017. At the time, Humabs was a small operation with only four people working in the laboratory, and their processes were highly unstructured. Data management was primarily done through paper documents and Microsoft Office files, with little to no digitalization in place. Despite their size, Humabs recognized the need for improvements in their internal processes and reached out to our consultancy for assistance.